Onconetix Acquires Realbotix in All-Stock Deal, Stock Price Plunges

Onconetix has acquired Realbotix, a US-based developer of AI-powered humanoid robots, in an all-stock transaction. The deal is expected to enhance shareholder value and close in H2 2026, subject to approvals. Upon closing, Realbotix Parent will own 75-90% of the combined company, with Andrew Kiguel becoming CEO. Onconetix, a commercial-stage biotechnology company, has traded between $1.15 and $47.68 over the past year and is currently trading at $1.22, down 33.98%.